Study study type PathologyT1T0Patientssample sizesROB Results

mUC - M - PDL1 positive metastatic/advanced UC (mUC) - maintenance (M) mUC - M - PDL1 positive

versus BSC
avelumab alone
JAVELIN Bladder 100 (PDL1>25%), 2020
  NCT02603432
RCTmUC - M - PDL1 positiveavelumabno treatmentpreviously untreated locally advanced or metastatic urothelial carcinoma whose disease did not progress on induction chemotherapy189 / 169some concern
conclusif
  • demonstrated 44 % decrease in deaths (OS) (PE)
  • suggested 31 % decrease in deaths (OS) (extension)
  • suggested 54 % decrease in PFS (extension)
  • suggested 44 % decrease in progression or deaths (PFS)